Site search
2807 results for '' found
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)
/research/clinical-trials/find-clinical-trials/a-phase-1-study-of-oral-ly3410738-in-patients-with-advanced-hematologic-malignancies-with-idh1-or-idh2-mutations-loxo-idh-20001-nct04603001
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/
/research/clinical-trials/find-clinical-trials/a-phase-3-open-label-randomized-study-of-fixed-duration-pirtobrutinib-loxo-305-plus-venetoclax-and-rituximab-versus-venetoclax-and-rituximab-in-previously-treated-chronic-lymphocytic-leukemia
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemi
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemi
/research/clinical-trials/find-clinical-trials/a-phase-3-open-label-randomized-study-of-loxo-305-versus-investigators-choice-of-idelalisib-plus-rituximab-or-bendamustine-plus-rituximab-in-btk-inhibitor-pretreated-chronic-lymphocytic-leukemi
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)
/research/clinical-trials/find-clinical-trials/transcatheter-aortic-valve-replacement-with-the-medtronic-transcatheter-aortic-valve-replacement-system-in-patients-at-low-risk-for-surgical-aortic-valve-replacement-nct02701283
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (N
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (N
/research/clinical-trials/find-clinical-trials/a-two-part-single-and-multiple-ascending-dose-trial-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-lbt-3627-in-healthy-subjects-and-in-subjects-with-parkinsons-disease-n
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous tre
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous tre
/research/clinical-trials/find-clinical-trials/a-phase-2-multicenter-open-label-long-term-safety-study-of-lp352-in-subjects-with-developmental-and-epileptic-encephalopathy-who-completed-study-lp352-201-and-are-candidates-for-continuous-tre
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory effi
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory effi
/research/clinical-trials/find-clinical-trials/a-phase-1b-2a-randomized-double-blind-placebo-controlled-parallel-group-dose-escalation-study-to-investigate-the-safety-tolerability-pharmacokinetics-pharmacodynamics-and-exploratory-effi
Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)
Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)
/research/clinical-trials/find-clinical-trials/long-term-outcomes-of-lidocaine-infusions-for-post-operative-pain-the-lolipop-trial-nct05072314
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab i
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab i
/research/clinical-trials/find-clinical-trials/a-phase-i-ii-open-label-multiple-centre-clinical-study-to-evaluate-the-safety-tolerability-pharmacokinetics-immunogenicity-and-preliminary-efficacy-of-lm302-in-combination-with-toripalimab-i
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as
/research/clinical-trials/find-clinical-trials/a-phase-i-ii-first-in-human-fih-open-label-dose-escalation-and-expansion-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-lm-108-an-anti-ccr8-mab-as